The effects of i.v. infusions (duration: 15 min) of 25 µg/kg/min methoxamine hydrochloride, an exclusively α-adrenergic sympathomimetic agent, on blood pressure, tolerance blood flow, and vascular resistance in the pulmonary, systemic and femoral circulations were investigated in anesthetized (glucochloralose-N2O) open chest dogs with artificial respiration. (1) Methoxamine caused a steady and continuous increase in systemic blood pressure, total peripheral- and femoral resistance and a continuous decrease in femoral blood flow throughout the entire duration of the infusion. This is in contrast to the effects of infused norepinephrine which exhibited a similar vasoconstrictive action, but this effect declined despite continuing infusion after the peak response had been reached (= acute tolerance). This difference confirms a theory proposed earlier [23] that acute norepinephrine tolerance is due to an interaction of the β-adrenergic with the vasoconstrictive effects of this catechol-amine. (2) The pulmonary circulatory effects of methoxamine differ essentially from its peripheral hemodynamic action. There was a decrease in pulmonary perfusion pressure due to a decrease in cardiac output, and the pulmonary vascular resistance fell slightly and insignificantly. In contrast, the systemic blood pressure and the total peripheral resistance were markedly increased. It is concluded that the reactivity of the pulmonary blood vessels to the vasoconstrictive property of methoxamine is much smaller than that of the systemic vasculature. (3) In a comparison of the pulmonary circulatory effects of 10 sympathomimetic agents with different ratios of α- to β-adrenergic properties it is pointed out that strong β-receptor stimulants increase the pulmonary perfusion pressure, whilst potent α-receptor stimulants lower it or do not change it. The pulmonary vascular resistance is increased most with those sympathomimetics which seem to possess approximately equally strong α- and β-mimetic properties, whilst during the administration of predominantly α- or β-adrenergic agents only very small changes in pulmonary vascular resistance were observed.